Chinese Academy of Sciences

Anhui New Star Pharmaceutical Development Co., Ltd.

Precedo Pharmaceuticals Co., Ltd

Yongfei Chen

Cheng Chen

Jing Liu

Qingsong Liu

Beilei Wang

Wenchao Wang

Aoli Wang

Hong Wu

Li Wang

Chen Hu

Wei Wang

Ziping Qi

Shuang Qi

Fengming Zou

Kailin Yu

Jiaxin Wu

Zheng Zhao

Qianmao Liang

Taoshan Jiang

The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same. 

Irreversible bruton's tyrosine kinase inhibitor

The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer. 

EGFR and ALK dual inhibitor

The present invention provides a Bruton's tyrosine kinase inhibitor, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method and use of using the Bruton's tyrosine kinase inhibitor to inhibit the tyrosine kinase activity or treat diseases, disorders or symptoms benefiting from the inhibition of the Bruton's tyrosine kinase (Btk) activity. 

Bruton's tyrosine kinase inhibitor

Growing community of inventors

Anhui, China

Yongfei Chen